Consolidated Statements of Income (Loss) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Total revenues	$ 351,410	$ 442,735	$ 410,596
Revenue from Contract with Customer, Product and Service	Collaborative arrangements revenue	Collaborative arrangements revenue	Collaborative arrangements revenue
Costs and expenses:
Research and development	$ 111,421	$ 116,085	$ 44,265
Selling, general and administrative	144,272	158,314	115,994
Restructuring	2,593	18,317
Acquired in-process research and development		1,095,449
Total costs and expenses	258,286	1,388,165	160,259
Income (loss) from operations	93,124	(945,430)	250,337
Other income (expense):
Interest expense and other financing costs	(33,034)	(21,629)	(7,598)
Interest and investment income	4,468	18,971	9,501
Gain on derivatives		19	182
Other	640
Other income (expense), net	(27,926)	(2,639)	2,085
Income (loss) before income taxes	65,198	(948,069)	252,422
Income tax expense	(64,318)	(83,490)	(77,357)
Net income (loss)	880	(1,031,559)	175,065
Less: Net loss attributable to noncontrolling interests		(29,320)
Net income (loss) attributable to Ironwood Pharmaceuticals, Inc.	$ 880	$ (1,002,239)	$ 175,065
Net income (loss) per share attributable to Ironwood Pharmaceuticals, Inc. stockholders - basic (in dollars per share)	$ 0.01	$ (6.45)	$ 1.13
Net income (loss) per share attributable to Ironwood Pharmaceuticals, Inc. stockholders - diluted (in dollars per share)	$ 0.01	$ (6.45)	$ 0.96
Weighted average shares used in computing net income (loss) per share attributable to Ironwood Pharmaceuticals, Inc. stockholders - basic (in shares)	159,083	155,435	154,366
Weighted average shares used in computing net income (loss) per share attributable to Ironwood Pharmaceuticals, Inc. stockholders - diluted (in shares)	160,084	155,435	186,312